Daljeet Kohli: Stock-Specific Buys in Pharma, Power; Avoid OMCs

Market expert Daljeet Kohli has advised Indian investors to prioritize stock-specific analysis and seek out quality companies trading at discounted valuations, rather than solely tracking the Nifty's overall movement. He specifically highlighted opportunities within the pharmaceutical sector, particularly those involved in the semaglutide market, and the broader power sector.

This guidance is significant for Indian traders as it suggests a shift from broad market momentum plays to a more granular, fundamental-driven investment strategy. With the Nifty potentially reaching 24,000, such expert advice helps investors identify pockets of value and growth amidst potentially stretched valuations in other segments, guiding capital allocation decisions.

The advice is positive for companies in the pharmaceutical sector, especially those with a presence in the semaglutide market, and power sector stocks. It offers a mixed to positive outlook for selective auto stocks, mid-cap banks, and housing finance companies. Conversely, it signals a negative sentiment for Oil Marketing Companies (OMCs), suggesting traders might consider reducing exposure or avoiding these stocks.

Traders should monitor specific company fundamentals within the recommended sectors, looking for strong balance sheets and growth prospects. Pay attention to quarterly results of pharma companies with semaglutide exposure and power sector players. For mid-cap banks and housing finance, evaluate asset quality and credit growth. Avoid OMCs until a clearer positive catalyst emerges.

• •Daljeet Kohli advises investors to focus on quality stocks at discounted prices, not just Nifty movement.
• •He highlights opportunities in pharmaceuticals, specifically the semaglutide market.
• •The power sector is also identified as a top pick.
• •Kohli suggests selective investments in autos, mid-cap banks, and housing finance.
• •He cautions against investing in oil marketing companies.